Antibody responses to pneumococcal and haemophilus vaccinations in patients with B-cell chronic lymphocytic leukaemia
Antibody responses to pneumococcal and haemophilus vaccinations in patients with B-cell chronic lymphocytic leukaemia
复制标题
DOI：
10.1016/s0264-410x(00)00409-6
复制
发表时间：
2001-02-08
期刊：
影响因子：
5.5
通讯作者：
Biesma, DH
中科院分区：
文献类型：
--
作者：
Hartkamp, A;Mulder, AHL;Biesma, DH
虽然推荐免疫功能低下的患者接种肺炎链球菌和b型流感嗜血杆菌疫苗，如B细胞慢性淋巴细胞白血病(B-CLL)，但其保护作用值得怀疑。我们研究了25例B-CLL患者对肺炎链球菌多糖疫苗(Papoovax-23(R))和流感嗜血杆菌结合b型疫苗(Act-Hib(R))的抗体反应。接种疫苗后，对肺炎球菌血清型和流感嗜血杆菌b抗体水平在保护范围内的患者分别从9例(38%)增加到12例(50%)，24例患者从8例(35%)增加到11例(48%)。对肺炎病毒23(R)和Act-Hib(R)抗体反应良好的患者B-CLL分期明显较慢，丙种球蛋白水平、总免疫球蛋白水平和免疫球蛋白亚类2、4水平较高，而可溶性CD23水平较低。因此，应在疾病病程早期诊断出B-CLL并测定接种后抗体水平后立即接种这些疫苗。(C)2001爱思唯尔科学有限公司。保留所有权利。
Although vaccination against Streptococcus pneumoniae (S. penumoniae) and Haemophilus influenzae type b (Hib) is recommended for immunocompromised patients, such as patients with B-cell chronic lymphocytic leukaemia (B-CLL), its protective effect is questionable. We studied antibody responses to pneumococcal polysaccharide vaccine (Pneumovax-23(R)) and to conjugated H. influenzae type b-vaccine (Act-Hib(R)) in 25 patients with B-CLL. After vaccination, the number of patients with antibody levels in the protective range against pneumococcal serotypes and H. influenzae b increased from 9 (38%) to 12 (50%), of 24 patients and from 8 (35%) to 11 (48%) of 23 patients, respectively. The patients with adequate antibody response to Pneumovax-23(R) and Act-Hib(R) had significantly less advanced stages of B-CLL, higher gammaglobulin levels, total IgG-levels and IgG-subclasses 2 and 4 levels, and lower levels of soluble CD23. Consequently, vaccination with these vaccines should be given as soon as the diagnosis of B-CLL is made early in the course of the disease with determination of post-vaccination antibody levels. (C) 2001 Elsevier Science Ltd. All rights reserved.